Botanix Pharmaceuticals (BOT) Q1 2026 TU earnings summary

Executive summary

• Sofdra prescriptions increased 50% quarter-over-quarter to 20,418 in Q1 FY26, driving significant net sales growth and strong commercial momentum.

• Net sales for Sofdra reached $7.1 million in Q1 FY26, up 65% from the prior quarter.

• Sales force expanded from 27 to 50 representatives, supporting further market penetration and productivity.

• All resources are focused on Sofdra, with other development programs on hold to maximize launch success.

• Maintained a robust capital position to fund ongoing growth and operational initiatives.

Financial highlights

• Gross-to-net yield improved to 23% in Q1 FY26, up from 21% in Q4 FY25, with a long-term target of 30–40%.

• Operating cash outflow decreased to $13.1 million in Q1 FY26, a $15.3 million improvement from the previous quarter.

• Cash and cash equivalents at quarter-end were $49.2 million, with $15.2 million in undrawn debt capacity.

• Product manufacturing costs dropped 81% to $2.2 million; operating costs fell 29%; G&A costs declined 22%.

• Inventory at $29 million, sufficient to support sales force expansion and future growth.

Outlook and guidance

• Continued double-digit revenue growth expected, driven by expanded sales force, high refill rates, and strong demand.

• Company anticipates achieving profitability with current funding and sales momentum.

• Medicaid coverage is being rolled out state-by-state, with further opportunities anticipated.